L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 3, 2004, Pages 204-208

  Tsurusawa, Masahito ^a   Chin, Motoaki ^a   Iwai, Asayuki ^a   Nomura, Keiko ^a   Maeba, Hideaki ^a   Taga, Takashi ^a   Higa, Takeshi ^a   Kuno, Tomoko ^a   Hori, Toshinori ^a   Muto, Akiko ^a   Yamagata, Miyo ^b  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Acute lymphoblastic leukemia; Asparaginase; Asparagine; Childhood

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTIBODY TITER; ARTICLE; BLOOD; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPLETION; ENZYME ACTIVITY; HUMAN; METABOLISM; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; ASPARAGINE; CHILD; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE;

EID: 10744233565     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0734-5     Document Type: Article

References (21)

1. Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, Werber G, Borste H, Wurthwein G, Jurgens H, Boos J (1997) Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol 96:675
2. Arbertsen BK, Schroder H, Ingerslev J, Jakobsen P, Avramis VI, Muller HJ, Carlsen NT, Schmiegelow K (2001) Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol 115:983
3. Asselin BL, Lorenson MY, Whitin JC, Coppola DJ, Kende AS, Blakely RL, Cohen HJ (1991) Measurement of serumL-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res 51:6568
4. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ (1993) Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 11:1780
5. Boos J (1997) Pharmacokinetics and drug monitoring of L-asparaginase treatment. Int J Clin Pharmacol Ther 35:96
6. Boos J, Werber G, Ahlke E, Schulze-Westhoff P, Nowak-Gottl U, Wurthwein G, Verspohl EJ, Ritter J, Jurgens H (1996) Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 32A:1544
7. Dolowy WC, Henson D, Cornet J, Sellin H (1966) Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer 19:1813
8. Gentile D, Zucchetti M, Conter V, Masera G, D'Incalci M (1994) Determination ofL-asparagine in biological samples in the presence of L-asparaginase. J Chromatogr B 657:47
9. Gentile D, Conter V, Rizzari C, Tschuemperlin B, Zucchetti M, Orlandoni D, D'Incalci M, Masera G (1996) L-asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposure to Erwinia L-asparaginase. Ann Oncol 7:725
10. Henze G, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D, Riehm H (1991) Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 78:1166
11. Hill JM, Roberts J, Loeb E, Khan A, MacLellan A, Hill RW (1967) L-asparaginase therapy for leukemia and other malignant neoplasms. JAMA 202:882
12. Muller HJ, Boos J (1998) Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 28:97
13. Oettgen HF, Old LJ, Boyse EA, Campbell HA, Philips FS, Clarkson BD, Tallal L, Leeper RD, Schwartz MK, Kim JH (1967) Inhibition of leukemias in man by L-asparaginase. Cancer Res 27:2619
14. Pinheiro JPV, Muller HJ, Schwabe D, Gunkel M, Da Palma C, Henze G, von Schutz V, Winkelhorst M, Wurthwein G, Boos J (2001) Drug monitoring of low-dose PEG-asparaginase (Oncasper™) in children with relapsed acute lymphoblastic leukaemia. Br J Haematol 113:115
15. Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG (1981) L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 41:4554
16. Rizzari C, Zucchetti M, Conter V, Diomed L, Bruno A, Gavazzi L, Paganini M, Sparano P, Lo Nigro L, Arico M, Milani M, D'Incalci M (2000) L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol 11:189
17. Takatsuka S, Kitaura K, Sato K, Tsuchiya J (1998) Fundamental examination and clinical application on IgE and IgG4 antibodies specific forL-asparaginase by f-ELISA. J Med Technol 42:233
18. Tsukimoto I, Matsui J, Iwashita H, Shigeta K, Suzuki H, Hashimoto T (1992) Improved measurements of anti-L-asparaginase IgG antibody and its clinical applications. Jpn J Clin Hematol 33:24
19. Tsurusawa M, Katano N, Yamamoto Y, Hirota T, Koizumi S, Watanabe A, Takeda T, Hatae Y, Yatabe M, Mimaya J, Gushiken T, Nishi K, Anami K, Kikuta A, Kanegane H, Asami K, Nishikawa K, Sekine I, Kawano Y, Iwai A, Furuyama T, Ijichi O, Miyake M, Mugishima H, Fujimoto T (1999) Improvement in CNS protective treatment in non-high risk childhood acute lymphoblastic leukemia, a report from the Japanese Children's Cancer and Leukemia Study Group (CCLSG). Med Pediatr Oncol 32:259
20. Vieira Pinheiro JP, Ahlke E, Nowak-Gottl U, Hempel G, Muller HJ, Lumkemann K, Schrappe M, Rath B, Fleischhack G, Mann G, Boos J (1999) Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol 104:313
21. Yasui Y (1991) Application of Shimadzu amino acid analysis system to biological sciences. Shimadzu Rev 47(4):365